Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum

Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.

Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsBrett Monia - Founder, ...

Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS)

In recent weeks, Ionis Pharmaceuticals announced that the FDA accepted a Priority Review for olezarsen in severe hypertriglyceridemia, released 2026 revenue guidance of US$800 million to US$825 ...

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

Ionis Pharmaceuticals Q4 Earnings Call Highlights

Ionis Pharmaceuticals (NASDAQ:IONS) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight what CEO Brett Monia called a “defining year,” pointing to the successful ...
AOL

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
Benzinga.com

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for ...

Ionis Pharmaceuticals: Q4 Earnings Snapshot

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $229 million in its fourth quarter. On a per-share basis, the Carlsbad, ...
Business Wire

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...
PharmiWeb

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –- Olezarsen sHTG launch preparations on track, sNDA submitted -- Exceeded 2025 financial guidance, 2026 ...
Benzinga.com

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...